StockData

Envoy Medical vs Nexalin Technology

COCH and NXL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How COCH and NXL compare

Envoy Medical is the larger company, worth 16 times as much as Nexalin Technology ($534M against $34.4M).

Nexalin Technology grew revenue faster over the last twelve months (24.2% versus −6.8% for Envoy Medical).

Nexalin Technology keeps more of each dollar of sales as profit, with a net margin of −4139% compared with −11305% at Envoy Medical.

Nexalin Technology scores higher on the StockData Score (7 against 5 for Envoy Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCOCHNXL
Size and price
Market cap$534M$34.4M
Share price$6.92$1.56
Change, 1 year942%−95.6%
Change, 5 years−92.9%–
Beta (5Y)1.362.73
Employees438
StockData Score
Total score57 (better)
Valuation score00
Growth score02 (better)
Performance score00
Health score55
Dividend score00
Valuation
P/S2581×158× (better)
P/B162×22.6× (better)
Growth
Revenue growth (TTM)−6.8%24.2% (better)
Profitability
Gross margin−386%86.2% (better)
Operating margin−11411%−4203% (better)
Net margin−11305%−4139% (better)
Return on equity–−240%
Return on invested capital–−2105%
Financial health
Debt / equity0.000.00
Current ratio1.73 (better)1.25
Altman Z-score−6.04 (better)−41.21
Piotroski F-score25 (better)
Dividends and buybacks
Buyback yield−5.7%–
Shareholder yield−5.7%0.00% (better)
Ownership
Held by institutions39.7%0.13%
Held by insiders–22.3%
Insider net buying, 12 months$8.2M–
Short interest, % of float–0.07%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.